{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:51:34Z","timestamp":1768272694061,"version":"3.49.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["23AIREA1045073"],"award-info":[{"award-number":["23AIREA1045073"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Renin-angiotensin system (RAS) modulators, including Angiotensin receptor blockers (ARB) and angiotensin-converting enzyme inhibitors (ACEI), are effective medications for controlling blood pressure. Cognitive deficits, including lack of concentration, memory loss, and confusion, were reported after COVID-19 infection. ARBs or ACEI increase the expression of angiotensin-converting enzyme-2 (ACE-2), a functional receptor that allows binding of SARS-CoV-2 spike protein for cellular invasion. To date, the association between the use of RAS modulators and the severity of COVID-19 cognitive dysfunction is still controversial. Purpose: This study addressed the following questions: 1) Does prior treatment with RAS modulator worsen COVID-19-induced cerebrovascular and cognitive dysfunction? 2) Can post-treatment with RAS modulator improve cognitive performance and cerebrovascular function following COVID-19? We hypothesize that pre-treatment exacerbates COVID-19-induced detrimental effects while post-treatment displays protective effects. Methods: Clinical study: Patients diagnosed with COVID-19 between May 2020 and December 2022 were identified through the electronic medical record system. Inclusion criteria comprised a documented medical history of hypertension treated with at least one antihypertensive medication. Subsequently, patients were categorized into two groups: those who had been prescribed ACEIs or ARBs before admission and those who had not received such treatment before admission. Each patient was evaluated on admission for signs of neurologic dysfunction. Pre-clinical study: Humanized ACE-2 transgenic knock-in mice received the SARS-CoV-2 spike protein via jugular vein injection for 2 weeks. One group had received Losartan (10 mg\/kg), an ARB, in their drinking water for two weeks before the injection, while the other group began Losartan treatment after the spike protein injection. Cognitive functions, cerebral blood flow, and cerebrovascular density were determined in all experimental groups. Moreover, vascular inflammation and cell death were assessed. Results: Signs of neurological dysfunction were observed in 97 out of 177 patients (51%) taking ACEIs\/ARBs prior to admission, compared to 32 out of 118 patients (27%) not receiving ACEI or ARBs. In animal studies, spike protein injection increased vascular inflammation, increased endothelial cell apoptosis, and reduced cerebrovascular density. In parallel, spike protein decreased cerebral blood flow and cognitive function. Our results showed that pretreatment with Losartan exacerbated these effects. However, post-treatment with Losartan prevented spike protein-induced vascular and neurological dysfunctions. Conclusion: Our clinical data showed that the use of RAS modulators before encountering COVID-19 can initially exacerbate vascular and neurological dysfunctions. Similar findings were demonstrated in the in-vivo experiments; however, the protective effects of targeting the RAS become apparent in the animal model when the treatment is initiated after spike protein injection.<\/jats:p>","DOI":"10.1371\/journal.pone.0304135","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T19:19:52Z","timestamp":1722280792000},"page":"e0304135","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Timing matters in the use of renin-angiotensin system modulators and COVID-related cognitive and cerebrovascular dysfunction"],"prefix":"10.1371","volume":"19","author":[{"given":"Mackenzi","family":"Meier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oriana","family":"DuFresne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2284-1623","authenticated-orcid":true,"given":"Kaleigh","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith N.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica C.","family":"Hermanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan P.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Abdelsaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8555-2039","authenticated-orcid":true,"given":"Maha","family":"Coucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"pone.0304135.ref001","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-med-042320-010427","article-title":"Neurologic Manifestations and Complications of COVID-19.","volume":"73","author":"MK Hensley","year":"2022","journal-title":"Annu Rev Med."},{"issue":"4","key":"pone.0304135.ref002","article-title":"COVID-19: from the structure and replication cycle of SARS-CoV-2 to its disease symptoms and treatment","volume":"72","author":"JB Zawilska","year":"2021","journal-title":"J Physiol Pharmacol"},{"issue":"2","key":"pone.0304135.ref003","doi-asserted-by":"crossref","first-page":"fcaa205","DOI":"10.1093\/braincomms\/fcaa205","article-title":"Frequent neurocognitive deficits after recovery from mild COVID-19","volume":"2","author":"MS Woo","year":"2020","journal-title":"Brain Commun"},{"issue":"1","key":"pone.0304135.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5501\/wjv.v11.i1.1","article-title":"Heart failure in COVID-19 patients: Critical care experience","volume":"11","author":"KJ John","year":"2022","journal-title":"World J Virol"},{"key":"pone.0304135.ref005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijid.2020.07.029","article-title":"Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis","volume":"99","author":"Y Zhou","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"10","key":"pone.0304135.ref006","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1161\/HYPERTENSIONAHA.122.19694","article-title":"Hypertension and Excess Risk for Severe COVID-19 Illness Despite Booster Vaccination","volume":"79","author":"JE Ebinger","year":"2022","journal-title":"Hypertension"},{"issue":"4","key":"pone.0304135.ref007","doi-asserted-by":"crossref","first-page":"e0022022","DOI":"10.1128\/msphere.00220-22","article-title":"Repressed Ang 1\u20137 in COVID-19 Is Inversely Associated with Inflammation and Coagulation.","volume":"7","author":"RM Carpenter","year":"2022","journal-title":"mSphere"},{"issue":"2","key":"pone.0304135.ref008","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40292-022-00506-9","article-title":"Hypertension and COVID-19: Current Evidence and Perspectives.","volume":"29","author":"G Gallo","year":"2022","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"6","key":"pone.0304135.ref009","first-page":"728","article-title":"COVID-19 and RAAS inhibitors: is there a final conclusion?","volume":"13","author":"M Talebi-Taher","year":"2021","journal-title":"Iran J Microbiol"},{"issue":"22","key":"pone.0304135.ref010","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26226945","article-title":"The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19.","volume":"26","author":"G El-Arif","year":"2021","journal-title":"Molecules"},{"key":"pone.0304135.ref011","article-title":"GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes","author":"J Bailey","year":"2022","journal-title":"Diabetologia"},{"issue":"9","key":"pone.0304135.ref012","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41440-020-0488-z","article-title":"SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs\/ARBs.","volume":"43","author":"MM Ciulla","year":"2020","journal-title":"Hypertens Res"},{"key":"pone.0304135.ref013","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2021.09.007","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: One year later","volume":"93","author":"F Angeli","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"1","key":"pone.0304135.ref014","doi-asserted-by":"crossref","first-page":"L156","DOI":"10.1152\/ajplung.00313.2002","article-title":"Angiotensin II and the fibroproliferative response to acute lung injury","volume":"286","author":"RP Marshall","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"pone.0304135.ref015","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/01.HYP.32.3.488","article-title":"Role of NADH\/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy","volume":"32","author":"AM Zafari","year":"1998","journal-title":"Hypertension"},{"issue":"4","key":"pone.0304135.ref016","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1124\/pharmrev.120.000281","article-title":"The Angiotensin AT(2) Receptor: From a Binding Site to a Novel Therapeutic Target.","volume":"74","author":"UM Steckelings","year":"2022","journal-title":"Pharmacol Rev"},{"issue":"4","key":"pone.0304135.ref017","doi-asserted-by":"crossref","first-page":"H1341","DOI":"10.1152\/ajpheart.00202.2011","article-title":"Acute and chronic angiotensin-(1\u20137) restores vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats.","volume":"301","author":"G Raffai","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1\u20133","key":"pone.0304135.ref018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-0115(00)00138-5","article-title":"an update","volume":"91","author":"RA Santos","year":"2000","journal-title":"Regul Pept"},{"issue":"1","key":"pone.0304135.ref019","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1124\/jpet.120.000397","article-title":"Targeting the Protective Arm of the Renin-Angiotensin System: Focused on Angiotensin-(1\u20137).","volume":"377","author":"S Khajehpour","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"pone.0304135.ref020","doi-asserted-by":"crossref","first-page":"117905","DOI":"10.1016\/j.lfs.2020.117905","article-title":"Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications","volume":"256","author":"N Banu","year":"2020","journal-title":"Life Sci"},{"issue":"2","key":"pone.0304135.ref021","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3988\/jcn.2021.17.2.155","article-title":"Pathomechanism and Management of Stroke in COVID-19: Review of Immunopathogenesis, Coagulopathy, Endothelial Dysfunction, and Downregulation of ACE2.","volume":"17","author":"PL Rahmawati","year":"2021","journal-title":"J Clin Neurol."},{"issue":"22","key":"pone.0304135.ref022","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216394","article-title":"SARS-CoV-2 Spike Protein Intensifies Cerebrovascular Complications in Diabetic hACE2 Mice through RAAS and TLR Signaling Activation.","volume":"24","author":"FN Burnett","year":"2023","journal-title":"Int J Mol Sci."},{"issue":"4","key":"pone.0304135.ref023","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/1715163520929373","article-title":"COVID-19 and the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"153","author":"MH St John","year":"2020","journal-title":"Can Pharm J (Ott)."},{"key":"pone.0304135.ref024","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.biopha.2017.05.062","article-title":"ACE-2\/Ang1-7\/Mas cascade mediates ACE inhibitor, captopril, protective effects in estrogen-deficient osteoporotic rats","volume":"92","author":"HM Abuohashish","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"1\u20132","key":"pone.0304135.ref025","first-page":"59","article-title":"Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition.","volume":"17","author":"CX Liu","year":"2011","journal-title":"Mol Med"},{"issue":"4","key":"pone.0304135.ref026","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00726-014-1889-6","article-title":"Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors","volume":"47","author":"RN Vuille-dit-Bille","year":"2015","journal-title":"Amino Acids"},{"issue":"19","key":"pone.0304135.ref027","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/heartjnl-2020-317336","article-title":"Treatment with ACE inhibitors or ARBs and risk of severe\/lethal COVID-19: a meta-analysis","volume":"106","author":"ME Flacco","year":"2020","journal-title":"Heart"},{"issue":"2","key":"pone.0304135.ref028","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/ehjcvp\/pvaa064","article-title":"A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers","volume":"7","author":"A Grover","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"pone.0304135.ref029","doi-asserted-by":"crossref","first-page":"703661","DOI":"10.3389\/fmed.2021.703661","article-title":"Mortality and Severity in COVID-19 Patients on ACEIs and ARBs-A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.","volume":"8","author":"R Singh","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"17","key":"pone.0304135.ref030","doi-asserted-by":"crossref","first-page":"e026143","DOI":"10.1161\/JAHA.122.026143","article-title":"Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.","volume":"11","author":"SR Gnanenthiran","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"7830","key":"pone.0304135.ref031","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"C Munoz-Fontela","year":"2020","journal-title":"Nature"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T19:20:19Z","timestamp":1722280819000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0304135"}},"subtitle":[],"editor":[{"given":"Michael","family":"Bader","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0304135","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}